The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The Treatment of Disc Herniation-Induced Sciatica With Infliximab: One-Year Follow-up Results of FIRST II, a Randomized Controlled Trial
Abstract
STUDY DESIGN: A randomized controlled trial. OBJECTIVES: To evaluate the long-term efficacy of infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-alpha), in patients with acute/subacute sciatica secondary to herniated disc. SUMMARY OF BACKGROUND DATA: The results of experimental studies and our open-label trial support the use of infliximab in sciatica. Here we report the 1-year results of a randomized controlled trial (FIRST II, Finnish Infliximab Related STudy) evaluating the efficacy and safety of a single infusion of infliximab for sciatic pain. METHODS: Inclusion criteria were unilateral sciatic pain with a disc herniation concordant with the symptoms and signs of radicular pain. Patients had to be candidates for discectomy. Criteria for discectomy included (in addition to a symptomatic disc herniation on MRI) neural entrapment (straight leg raising [SLR] < or =60 degrees ) with either a short-term (2-4 weeks) severe or long-term (4-12 weeks) moderate leg pain. Forty patients were allocated to a single intravenous infusion of either infliximab 5 mg/kg or placebo. Differences in the clinical examination parameters (straight leg raise [SLR], muscle strength, sensory defects, tendon reflexes), patient-reported symptoms (leg and back pain using a visual analog scale [VAS], Oswestry disability, quality-of-life [RAND-36]), sick leaves, number of discectomies, and adverse effects between the two treatment groups over the 1-year follow-up were compared using Mann-Whitney U test or Student's t test, repeated-measures analysis, or Cox proportional hazards model. Logistic regression was used to assess the predictors of good response. RESULTS: Sixty-seven percent of patients in the infliximab group reported no pain at 52 weeks compared with 63% in the control group (P = 0.72). Similar efficacy was observed between treatment groups for other outcomes. Eight patients in each group required surgery. Three nonserious adverse reactions were encountered in the infliximab group. The response (irrespective of the treatment) was significantly better with shorter symptom duration and less SLR restriction at baseline. Patients in the infliximab group appeared to especially benefit in cases of a L4-L5 (or L3-L4) herniation and if a Modic change was colocalized at the symptomatic level. CONCLUSIONS: Although the long-term results of this randomized trial do not support the use of infliximab compared with placebo for lumbar radicular pain in patients with disc herniation-induced sciatica, further study in a subgroup of patients with L4-L5 or L3-L4 herniations, especially in the presence of Modic changes, appears to be warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Placebo and Opioid Analgesia-- Imaging a Shared Neuronal Network
Petrovic, P., Kalso, E., Petersson, K. M., & Ingvar, M. (2002) · Science · doi:10.1126/science.1067176 · Cited by 1,488
The RAND-36 measure of health-related quality of life
Hays, R. D., & Morales, L. S. (2001) · Annals of Medicine · doi:10.3109/07853890109002089 · Cited by 1,460 · cited 4×
“63 Sensory defect (%) Medial leg Baseline 3 (14) 1 (5) 4 (10) 0.”
Influential
Cited by
Role of cytokines in intervertebral disc degeneration: pain and disc content
Risbud, M. V., & Shapiro, I. M. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.160 · Cited by 1,767
Neuropathic pain: mechanisms and their clinical implications
Cohen, S. P., & Mao, J. (2014) · BMJ · doi:10.1136/bmj.f7656 · Cited by 802
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Self-citationTNF-α and neuropathic pain - a review
Leung, L., & Cahill, C. M. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-27 · Cited by 630
Le Maitre, C. L., Hoyland, J. A., & Freemont, A. J. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2275 · Cited by 580
Metadata
- Authors
- Korhonen, T., Karppinen, J., Paimela, L., Malmivaara, A., Lindgren, K.-A., Bowman, C., Hammond, A., Kirkham, B., Järvinen, S., Niinimäki, J., Veeger, N., Haapea, M., Torkki, M., Tervonen, O., Seitsalo, S., & Hurri, H.
- Venue
- Spine
- Published
- 2006-11
- Volume
- 31
- Issue
- 24
- Pages
- 2759-2766
- ISSN
- 0362-2436 (ISSN-L)
- OpenAlex
- W2120758082
- Cited by
- 174
- References
- 2
- FWCI
- 5.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Treatment of Disc Herniation-Induced Sciatica With Infliximab: One-Year Follow-up Results of FIRST II, a Randomized Controlled Trial. https://app.cochat.ai/papers/10.1097/01.brs.0000245873.23876.1e
- The paper
- Korhonen, T., Karppinen, J., Paimela, L., Malmivaara, A., Lindgren, K.-A., Bowman, C., Hammond, A., Kirkham, B., Järvinen, S., Niinimäki, J., Veeger, N., Haapea, M., Torkki, M., Tervonen, O., Seitsalo, S., & Hurri, H. (2006). The Treatment of Disc Herniation-Induced Sciatica With Infliximab: One-Year Follow-up Results of FIRST II, a Randomized Controlled Trial. Spine. https://doi.org/10.1097/01.brs.0000245873.23876.1e
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.